Analysis of the clinical efficacy of Qingchang Yuyang Decoction retention enema combined with hyperbaric oxygen in treating 54 cases of ulcerative colitis
10.3760/cma.j.cn311847-20210508-00143
- VernacularTitle:清肠愈疡汤留置灌肠联合高压氧治疗溃疡性结肠炎54例疗效分析
- Author:
Chaoqing LIU
1
;
Peng SUN
;
Xinying YE
;
Lijuan LU
Author Information
1. 265200 山东省烟台，烟台市莱阳中心医院消化内科
- Publication Type:Journal Article
- Keywords:
Ulcerative colitis;
Qingchang Yuyang Decoction;
Enema;
Hyperbaric oxygen;
Mesalazine
- From:
Chinese journal of nautical medicine and hyperbaric medicine
2021;28(5):612-616
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical efficacy and mechanism of Qingchang Yuyang Decoction retention enema combined with hyperbaric oxygen (HBO) in treating ulcerative colitis.Methods:A total of 92 patients with ulcerative colitis treated in the Department of Gastroenterology of Laiyang Central Hospital from April 2016 to May 2020 were selected as the research objects and were divided into observation group and control group according to the treatment methods. There were 54 cases in the observation group and 38 cases in the control group. The patients in the control group were given oral mesalazine, and were treated with Qingchang Yuyang Decoction retention enema once a day. The patients in the observation group were additionally treated with HBO on the basis of the treatment of the control group. The therapeutic effects were evaluated by colonoscopy grading criteria and clinical symptom score; and the clinical efficacy of the two groups was assessed by the modified Mayo endoscopic score (MMES). The quantitative analysis of the expression levels of serum asymmetric dimethylarginine (ADMA) in the two groups were conducted by fluorescence derivatives and capillary electrophoresis (CE); the expression levels of serum tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) were detected by enzyme-linked immunosorbent assay (ELISA). After six months of follow-up, the recurrence rates of the two groups were statistically analyzed.Results:The total effective rate in the observation group (90.74%) was significantly higher than that in the control group (73.68%), with a statistically significant difference ( χ2=5.893, P<0.05). The total score of clinical symptom assessment in the observation group after treatment (0.94±0.13) was significantly lower than that in the control group (1.33±0.16), with a statistically significant difference ( P<0.05). The total score of colonoscopy examination in the observation group after treatment (0.97±0.10) was significantly lower than that in the control group (1.41±0.16), with a statistically significant difference ( P<0.05). The Mayo scores of the two groups after treatment were significantly lower than those before treatment ( P<0.05), and the Mayo score of the observation group after treatment was lower than that of the control group after treatment ( P<0.05). After four courses of treatment, the levels of ADMA, TNF-α, and IL-6 in the two groups were significantly decreased, and the levels of ADMA, TNF-α, and IL-6 in the observation group after treatment were significantly lower than those in the control group after treatment ( P<0.05 or P<0.01). All the patients were followed up for six months. The recurrence rates of ulcerative colitis were 10.2% (5/49) in the observation group and 25.0% (7/28) in the control group, respectively ( χ2=6.013, P<0.05). Conclusion:Qingchang Yuyang Decoction retention enema after HBO treatment of ulcerative colitis can reduce the inflammation of intestinal wall and promote the healing of ulcer. It has better clinical efficacy and lower recurrence rate than mesalazine combined with Qingchang Yuyang Decoction. Therefore, it can be widely applied in clinical practice.
